360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Cipher Pharmaceuticals Inc

Type: Company

Name: Cipher Pharmaceuticals Inc

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Ranbaxy Laboratories Ltd

Cipher Pharma Continues To Deliver

Home » Blogs » On May 3, 2013, Cipher Pharmaceuticals (CPHMF.PK) reported financial results for the first quarter 2013. Total revenue in the quarter was $3.3 million, up 82% over the first quarter 2012 and nicely ahead of our estimate for revenue of $2.6 ... [Published BioPortfolio - May 06 2013]

Entities: Ranbaxy Laboratories Ltd, Cipher Pharmaceuticals Inc, Biotechnology

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Air Canada

Canadian earnings declared Friday: Air Canada, GMP Capital Inc., Cipher Pharmaceuticals

TORONTO - Canadian earnings declared Friday:Air Canada (TSX:AC.A, AC.B): First-quarter ended March 31, 2013, net loss $260 million, net loss 95 cents per share; 2012, net loss $274 million, net loss 99 cents per share. Revenue: 2013, $2.95 billion; 2012, ... [Published Brandon Sun - May 03 2013]

Entities: Cipher Pharmaceuticals Inc, GMP Capital Inc, Air Canada

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Dril-Quip Inc

U.S./Canada daily earnings hits & misses May 03 - 0800 ET

May 3 (Reuters) - The following U.S.- and Canada-listed companies reported earnings on Friday. This list shows whether they beat, met or missed Wall Street analysts' forecasts. It also shows the difference between analysts' expectations and reported results. ... [Published Globe and Mail - May 03 2013]

Entities: Canada, Cipher Pharmaceuticals Inc, Johnson Outdoors Inc, Dril-Quip Inc, Olympic Steel Inc

First reported May 03 2013 - Updated May 03 2013 - 2 reports

Cipher Pharmaceuticals earns $1.5-million in Q1

Cipher Pharmaceuticals Inc. today released its financial and operational results for the three months ended March 31, 2013.Q1 2013 HighlightsNet revenue increased by 82% over Q1 2012 to $3.3 million.EBITDA of $ 1.7 million versus $0.3 million in Q1 2 ... [Published Stockwatch - May 03 2013]

Entities: Cipher Pharmaceuticals Inc, Canada, International Industries Ltd., Tramadol, isotretinoin

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Tramadol

Cipher, Tecnofarma sign supply agreement for extended-release tramadol

Cipher Pharmaceuticals has entered into a definitive distribution and supply agreement with Tecnofarma International under which Cipher has granted Tecnofarma the exclusive right to market and distribute CIP-TRAMADOL ER in Latin America. ... [Published PBR - News - May 01 2013]

Entities: Tramadol, Cipher Pharmaceuticals Inc

First reported Apr 29 2013 - Updated Apr 29 2013 - 3 reports

Toronto stock exchange

Cipher Pharmaceuticals completes Latin American distribution. . .

Cipher Pharmaceuticals completes Latin American distribution and supply agreement for extended-release tramadolCanada NewswireToronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, April 29, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF) ... [Published Equities.com - Apr 29 2013]

Entities: Cipher Pharmaceuticals Inc, Tramadol, Toronto stock exchange, Larry Andrews, Canada

First reported Apr 11 2013 - Updated Apr 11 2013 - 1 reports

Positive Share Price Performance in Q1 2013 for the Canadian Healthcare Sector (Part 1)

In order to assess share price performance among the Canadian public healthcare companies, I have selected a portfolio of 118 companies for the 2013 assessment. The portfolio has been split into three parts according to the closing share price on ... [Published The Cross-Border Biotech Blog - Apr 11 2013]

Entities: Share Price, Health Care, Rising Prices

First reported Feb 21 2013 - Updated Feb 21 2013 - 1 reports

2012 Canadian Healthcare Share Price Performance – volatile with opportunities

A group of 96 Canadian healthcare companies, which was assessed for 2012 share price performance is extremely diverse, with market caps ranging from about $1 million to $10 billion, but most less than $100 million. The 2012 share price performance ... [Published The Cross-Border Biotech Blog - Feb 21 2013]

Entities: Share Price, Health Care, Audiotech Healthcare Corp, Cipher Pharmaceuticals Inc

Quotes

...the addition of new product revenue streams, especially the strong early results from Absorica," said Larry Andrews, President and CEO of Cipher. "Building off this good start to the year, we are working toward the Canadian launch of Epuris by Q3 and have recently added experienced marketing and sales leadership to help us build our commercial presence in Canada. In addition, we recently licensed out the Latin American rights for our extended-release tramadol product to Tecnofarma International, which has deep experience in pain therapeutics and a large sales team in the region."

Cipher Pharmaceuticals earns $1.5-million in Q1 [Published Stockwatch - May 03 2013]

...marketed products and generate additional revenue streams," said Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals. "Tecnofarma is a significant player in the region with deep experience in pain management, which positions them well to introduce our extended-release tramadol product in key Latin American markets."

Cipher Pharmaceuticals completes Latin American distribution. . . [Published Equities.com - Apr 29 2013]

Ashish Anvekar, senior director, Ranbaxy Laboratories Inc. said, "We are most pleased to make Absorica available as a valuable option for dermatologists and a subset of patients who suffer from severe recalcitrant nodular acne. Absorica will be the flagship brand of the Ranbaxy dermatology product portfolio in the US."

Ranbaxy launches Absorica capsules in US market [Published PharmaBiz - Nov 26 2012]

...Canadian dermatologists and patients who require treatment for severe recalcitrant nodular acne," said Larry Andrews, president and CEO of Cipher. "The approval of Epuris is a critical milestone in our plans to create a commercial presence in dermatology and other specialty markets in Canada. Pre-commercial activities have commenced, including the addition, in the coming months, of a specialised dermatology sales and marketing team in preparation for the launch in Q2 2013."

Health Canada approves Cipher Pharma's Epuris to treat severe acne [Published PharmaBiz - Nov 24 2012]

More Content

sort by: Date \| Relevance
Ranbaxy's growth in trouble with quality issues... [Published PharmaBiz - May 13 2013]
Cipher Pharma Continues To Deliver [Published BioPortfolio - May 06 2013]
Cipher Pharma Continues To Deliver [Published Seeking Alpha - May 06 2013]
Canadian earnings declared Friday: Air Canada, ... [Published Brandon Sun - May 03 2013]
U.S./Canada daily earnings hits & misses May 03... [Published Globe and Mail - May 03 2013]
Cipher Pharmaceuticals earns $1.5-million in Q1 [Published Stockwatch - May 03 2013]
U.S./Canada daily earnings hits & misses May 03... [Published Globe and Mail - May 03 2013]
Cipher reports record financial results for Q1 ... [Published Canada NewsWire - May 03 2013]
Cipher, Tecnofarma sign supply agreement for ex... [Published PBR - News - May 01 2013]
Cipher Pharmaceuticals completes Latin American... [Published Equities.com - Apr 29 2013]
Cipher to distribute tramadol through Tecnofarma [Published Stockwatch - Apr 29 2013]
Cipher Pharmaceuticals completes Latin American... [Published Canada NewsWire - Apr 29 2013]
Monday Deal Review: April 29, 2013 [Published The Cross-Border Biotech Blog - Apr 29 2013]
Positive Share Price Performance in Q1 2013 for... [Published The Cross-Border Biotech Blog - Apr 11 2013]
Who can you meet at Partnerships in Clinical Tr... [Published Partnerships in Clinical Trials - Apr 01 2013]
2012 Canadian Healthcare Share Price Performanc... [Published The Cross-Border Biotech Blog - Feb 21 2013]
Ranbaxy launches Absorica capsules in US market [Published PharmaBiz - Nov 26 2012]
Health Canada approves Cipher Pharma's Epuris t... [Published PharmaBiz - Nov 24 2012]
Ranbaxy gets US approval to launch Absorica [Published Topnews.in - May 30 2012]

Blogs

sort by: Date \| Relevance
Cipher, Tecnofarma sign supply agreement for ex... [Published PBR - News - May 01 2013] Cipher Pharmaceuticals has entered into a definitive distribution and supply agreement with Tecnofarma International under which Cipher has granted Tecnofarma the exclusive right to market and distribute CIP-TRAMADOL ER in Latin America. ...
Monday Deal Review: April 29, 2013 [Published The Cross-Border Biotech Blog - Apr 29 2013] Welcome to your Monday Biotech Deal Review for April 29, 2013! This week saw Ergoresearch and Amorfix close their previously announced private offerings. Trimel, meanwhile, has raised $40 million from their public offering of 50,000,000 common shares. ...
Positive Share Price Performance in Q1 2013 for... [Published The Cross-Border Biotech Blog - Apr 11 2013] In order to assess share price performance among the Canadian public healthcare companies, I have selected a portfolio of 118 companies for the 2013 assessment. The portfolio has been split into three parts according to the closing share price on ...
Who can you meet at Partnerships in Clinical Tr... [Published Partnerships in Clinical Trials - Apr 01 2013] Partnerships in Clinical Trials 2013 brings together 1500+ clinical decision makers for four days of insightful content, connections and knowledge sharing that pushes the boundaries of drug development and provides you with an enhanced roadmap to ...
2012 Canadian Healthcare Share Price Performanc... [Published The Cross-Border Biotech Blog - Feb 21 2013] A group of 96 Canadian healthcare companies, which was assessed for 2012 share price performance is extremely diverse, with market caps ranging from about $1 million to $10 billion, but most less than $100 million. The 2012 share price performance ...